Actively Recruiting
99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors
Led by Nanjing First Hospital, Nanjing Medical University · Updated on 2025-03-11
20
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
At present, radiopharmaceuticals targeting FAP have been developed for the diagnosis and treatment of various tumors. Considering the problems of fast tumor tissue clearance and short retention time in small molecule FAP inhibitors based on quinoline rings, this project optimized their ligands and developed a new FAP targeted technetium labeled molecular imaging probe for SPECT/CT imaging research to evaluate its safety in clinical application and its effectiveness in tumor diagnosis.
CONDITIONS
Official Title
99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Volunteer subjects or patients who sign informed consent
- Any gender, aged between 18 and 75 years old inclusive
- Tumor detected by other imaging methods
- Patients with tumors who may undergo surgery or biopsy for final pathological diagnosis
- Kidney glomerular filtration rate (GFR) greater than 50 ml/min
- Effective renal plasma flow (ERPF) greater than 280 ml/min
- Platelet count (PLT) above 75,000/µL
- White blood cell (WBC) count above 3,000/µL
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 3 times the normal value
You will not qualify if you...
- History of allergy to similar drugs or current allergic diseases
- Currently in clinical research on other drugs or participated in clinical research on drugs (except vitamins and minerals)
- Other difficult-to-control clinical problems such as hepatitis C, active hepatitis B, serious chronic infections, or serious mental, neurological, cardiovascular, or respiratory diseases
- Abnormal liver or kidney function with GFR less than 50 ml/min
- Tumor load greater than 50% or obvious spinal cord compression
- Expected survival less than 6 months
- Chemotherapy performed within last 6 months
- Severe acute diseases or serious refractory mental disorders
- Pregnant or lactating women
- Physical condition unsuitable for radiological examination
- Other conditions deemed inappropriate by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanjing First Hospital
Nanjing, Jiangsu, China, 210006
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here